Provider: View Press Release
Type: Link
Title: GSK enters exclusive license agreement with Hansoh for HS-20093 | GSK
Description: Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates.
Provider: View Press Release
Type: Link
Title: Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial | GSK
Description: Results reinforce development approach of using Jemperli as a backbone in immuno-oncology-based combination therapies
Provider: View Press Release
Type: Link
Title: Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk | GSK
Description: Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.
Provider: View Press Release
Type: Link
Title: GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer | GSK
Description: European Commission converts previous conditional approval to full approval as monotherapy for second-line dMMR/MSI-H endometrial cancer.
Provider: View Press Release
Type: Link
Title: New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions | GSK
Description: Findings to be presented at the Global Coalition on Aging’s Silver Economy Forum 2023.
Provider: View Press Release
Type: Link
Title: New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence | GSK
Description: A new GSK survey shows a large number of adults do not understand how shingles may be triggered.